Last reviewed · How we verify
Delapril, Delapril-Manidipine Fixed combination
Delapril is an ACE inhibitor that reduces blood pressure by blocking angiotensin II formation, combined with manidipine, a calcium channel blocker that causes vasodilation.
Delapril is an ACE inhibitor that reduces blood pressure by blocking angiotensin II formation, combined with manidipine, a calcium channel blocker that causes vasodilation. Used for Hypertension.
At a glance
| Generic name | Delapril, Delapril-Manidipine Fixed combination |
|---|---|
| Sponsor | Mario Negri Institute for Pharmacological Research |
| Drug class | ACE inhibitor / Calcium channel blocker combination |
| Target | ACE (angiotensin-converting enzyme) and L-type calcium channels |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Delapril inhibits angiotensin-converting enzyme (ACE), preventing the conversion of angiotensin I to angiotensin II, thereby reducing vasoconstriction and aldosterone secretion. Manidipine blocks L-type calcium channels in vascular smooth muscle, causing direct vasodilation. The fixed combination provides complementary antihypertensive effects through two distinct mechanisms.
Approved indications
- Hypertension
Common side effects
- Cough
- Dizziness
- Headache
- Hyperkalemia
- Peripheral edema
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: